Boston gets $19m from Cordis for stent patent case
This article was originally published in Clinica
Boston Scientific has won $19.5m in damages in a patent infringement case against its coronary stent rival, Johnson & Johnson's Cordis. The jury in the Delaware district court awarded the company $18.5m in lost profits and $1m in "reasonable royalties". Boston had initially sought $34m in damages (www.clinica.co.uk, 6 May 2011), which would have represented more than half of the $60m Cordis made in sales of the infringing stent, the 2.25mm Cypher. The profit made from this stent is around $14m. Boston had filed the suit against Cordis in December 2009; in April, Cordis was found guilty of infringing Boston's Jang patent, and it was later determined that the infringement was wilful.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.